Antikoagulation bei chronischem Vorhofflimmern

J. Harenberg; D. L. Heene

doi:10.1055/s-0038-1655275

Hämostaseologie, Table of Contents

Hamostaseologie 1989; 09(05): 227-236
DOI: 10.1055/s-0038-1655275

Originalarbeiten

Schattauer GmbH

Antikoagulation bei chronischem Vorhofflimmern

J. Harenberg

¹1. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim

,

D. L. Heene

¹1. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim

› Author Affiliations

Abstract

Zusammenfassung

Bei Patienten mit chronischem Vorhofflimmern ohne systemische Embolien ist eine Langzeitprophylaxe bei gleichzeitiger Herzklappenerkrankung, Kardiomyopathie, Herzwandaneurysma oder intrakardialem Thrombus indiziert. Bei chronischem, nichtrheumatischen Vorhofflimmern ohne Embolien sollte nach den neuesten Untersuchungen (95) auch eine Antikoagulation erfolgen. Bei einem idiopathischen Vorhofflimmern ohne eine Herzerkrankung wird nicht antikoaguliert. Insbesondere bei Kontraindikationen zur oralen Antikoagulation bietet das niedermolekulare Heparin CY 216 eine Alternative zur Behandlung. In einer ersten Untersuchung konnte gezeigt werden, daß bei chronischem Vorhofflimmern ohne eine Embolie durch 1×36 mg CY 216 täglich subkutan über 6 Monate eine Reduktion der Inzidenz von Embolien erreicht wird. Insbesondere bei Patienten mit bereits stattgehabten Embolien scheint diese Prophylaxe wirksam zu sein.

Full Text

References

LITERATUR
1 Åberg H. 1. A study of atrial thrombosis and systemic embolism in a necropsy material. Acta Med Scand 1969; 185: 373-9.
2 Abildgaard U. Inhibition of the thrombinfibrinogen reaction by heparin and purified cofactor. Scand J Haematol 1968; 05: 440-5.
3 Anderson D C. Brain cardioembolism. Issues in diagnosis and management. Postgrad Med 1987; 82: 48-57.
4 Andriouli G, Mastacchi R, Barbanti M, Sarret M. Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low-molecular-weight heparin in rats. Haemostasis 1985; 15: 324-30.
5 Askey J M, Bernstein S. The management of rheumatic heart disease in relation to systemic arterial embolism. Prog Cardiovasc Dis 1960; 03: 220-32.
6 Barrowcliffe T W, Curtis A D, Tomlinson T P, Hubbard A R, Johnson E A, Thomas D P. Standardization of low-molecularweight heparins: a collaborate study. Thromb Haemost 1985; 54: 675-9.
7 Barrowcliffe T W, Johnson E A, Eggleton C A, Kemball-Cook G, Thomas D P. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979; 41: 573-83.
8 Barrowcliffe T W, Johnson R A, Eggleton C A, Thomas D P. Anticoagulant activities of lung and mucous heparins. Thromb Res 1977; 12: 27-36.
9 Beer D T, Ghitman B. Embolization from the atria in arteriosklerotic heart disease. JAMA 1961; 177: 287-91.
10 Bergqvist D, Nilsson B, Hedner U, Pedersen P C, Ostergaard P B. The effect of heparin fragments of different molecular weights on experimental thrombosis and haemostasis. Thromb Res 1985; 38: 589-601.
11 Biller J, Massey E W, Marier J R, Adams H P, Davis J N, Bruno A, Henriksen R A, Linhardt R J, Goldstein L B, Alberts M, Kisker C T, Toffol G J, Greenberg C S, Banwart K J, Bertels C, Beck D W, Walker M, Magnani H N. A dose excalation study of ORG 10172 (low molecular weight heparinoid) in stroke. Neurology 1989; 39: 262-5.
12 Brandt F N, Abbott R D, Kannel W B, Wolf P A. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 1985; 254: 3449-53.
13 Bratt G, Törnebohm E, Lockner D, Bergström K. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemost 1985; 53: 208-11.
14 Broze Jr. G. Regulatory inhibitor of the tissue factor pathway. Thromb Haemost 1989; 62: 463 (abstr).
15 Calandre I, Ortega J J F, Bernejo F, Portera A. Anticoagulation and hemorrhagic infarction in cerebral embolism secondary to rheumatic heart disease. Arch Neurol 1984; 41: 1152-4.
16 Caplan L. Intracerebral Hemorrhage Revisited. Neurology 1988; 38: 624-7.
17 Carter A V. Prognosis of cerebral embolism. Lancet 1965; II: 514-9.
18 Carter C J, Kelton J G, Hirsh J, Cerskus A, Santos A V, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-45.
19 Carter C J, Kelton J G, Hirsh J, Gent M. Relationship between the antithrombotic and anticoagulant effects of low-molecular-weight hepatin. Thromb Res 1981; 21: 169-74.
20 Cerebral Embolism Study Group. Cardioembolic stroke, early anticoagulation, and brain hemorrhage. Arch Intern Med 1987; 147: 636-40.
21 Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983; 14: 668-76.
22 Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Stroke 1984; 15: 779-89.
23 Chancellor A M, Glasgow G L, Ockelford P A, Johns A, Smith J. Etiology, prognosis, and hemostatic function after cerebral infarction in young adults. Thromb Haemost 1989; 62: 1876 (abstr).
24 Cheng T O. Warfarin to prevent thromboembolism in chronic atrial fibrillation. (Letter to the Editor). Lancet 1989; I: 670.
25 Chesebro J H, Fuster V, Elveback L R, McGoon D C, Pluth J R, Puga F J, Wallace R B, Danielson G K, Orszulak T A, Piehler J M, Schaff H V. Trial of combined warfarin plus dipyridamol or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamol. Am J Cardiol 1983; 51: 1537-41.
26 Choay J, Petitou M, Lormeau P, Sinay B, Casu B, Gatti G. Structure activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III. Biochem Biophys Res Commun 1983; 116: 492-9.
27 Close J B, Evans D W, Bailey S M. Persistent lone atrial fibrillation: it’s prognosis after clinical diagnosis. J R Coll Gen Pract 1979; 29: 547-9.
28 Cosgriff S W. Chronic anticoagulant therapy in recurrent embolism of cardiac origin. Ann Int Med 1953; 38: 278-87.
29 Dale J, Myhre E, Storstein O, Stormorken H, Efskind L. Prevention of arterial thromboembolism with acetylsalicylic acid: a controlled clinical study in patients with aortic ball valves. Am Heart J 1977; 94: 101-11.
30 Del Zoppo J G, Zeumer H, Harker L A. Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986; 17: 595-607.
31 Denton J, Lane D A, Thunberg L, Slater A M, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J 1983; 209: 455-60.
32 Doutremepuich C, Toulemonde F, Bousquet F, Bonini F. Comparison of the haemorrhagic effects of unfractionated heparin and a low-molecular-weight heparin fraction (CY 216) in rabbits. Thromb Res 1986; 43: 691-5.
33 Drake M E, Shin C. Conversion of ischemic to hemorrhagic infarction by anticoagulant administration. Arch. Neurol 1983; 40: 44-6.
34 Easton J D, Sherman D G. Management of cerebral embolism of cardiac origin. Stroke 1980; 11: 433-42.
35 Eggleton C A, Barrowcliffe T W, Merton R E, Thomas D P. In vitro and in vivo studies of the anti-Xa activity of heparin. Thromb Res 1981; 24: 319-28.
36 Evans W, Swan P. Lone auricular fibrillation. Br Heart J 1954; 16: 189-94.
37 Fairfax A J, Lambert C D, Leatham A. Systemic embolism in chronic sinoatrial disorder. N Engl J Med 1976; 295: 190-2.
38 Fareed J, Kumar A, Walenga J M, Emaneue R M, Williamson K, Hoppensteadt D. Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv Rev Fr Hematol 1984; 26: 267-75.
39 Fareed J, Walenga J M, Kumar A, Rock A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Haemostas 1985; 11: 155-75.
40 Fisher C M, Adams R D. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. Neuropath Exp Neurol 1951; 10: 92-4.
41 Fisher C M. Reducing risks of cerebral embolism. Geriatrics 1979; 34: 59-66.
42 Fisher M, Francis R. Thrombin and plasmin activity in cerebral ischemia. Thromb Haemost 1989; 62: 1873 (abstr).
43 Flegel K M, Shipley M J, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987; I: 526-9.
44 Fletcher A P, Alkjaersig N, Lewis M, Tulevski V, Davies A, Brooks J E, Hardin W B, Landau W M, Raichle M E. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976; 07: 135-42.
45 Forfar J C. A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment. Br Heart J 1979; 42: 128-32.
46 Freeman J, Wexler J, Howard F. Anticoagulants for treatment of atrial fibrillation. J Am Med Ass 1963; 184: 73-6.
47 Gajewsky J, Singer R B. Mortality in an insured population with atrial fibrillation. JAMA 1981; 245: 1540-4.
48 Garcia J H, Lowry S L, Briggs L. Brain capillaries expand and rupture in areas of ischemia and reperfusion. In: Cerebrovascular Diseases. Reivich M, Hurtig H I. (eds). New York: Raven Press; 1983: 169-80.
49 Godtfredson J. Atrial fibrillation: course and prognosis a follow-up study of 1212 cases. In: Atrial fibrillation. Kulbertus H E, Olsson S B, Schleppeer M. (eds). 2nd . ed. Mölndal (Schweden):: Hässle AB; 1984: 134-47.
50 Gurwitz J H, Goldberg R J, Holden A, Knapic N, Ansell J. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med 1988; 148: 1733-6.
51 Harenberg J, de Vries J X, Weber E, Zimmermann R. Beeinflussung der Blutgerinnung durch ein niedermolekulares Heparin. Dtsch Med Wochenschr 1984; 109: 951-4.
52 Harenberg J, de Vries J X, Weber E, Zimmermann R. Pharmakodynamik niedermolekularen Heparins nach intravenöser Verabreichung. Med Welt 1984; 35: 1371-4.
53 Harenberg J, Giese C h, Knödler A, Zimmermann R, Schettler G. Antagonisierung von niedermolekularem Heparin durch Protaminchlorid. Herz Kreisl 1986; 18: 578-81.
54 Harenberg J, Gnasso A, de Vries J X, Zimmermann R, Augustin J. Anticoagulant and lipolytic effects of a low-molecular-weight heparin fraction. Thromb Res 1985; 39: 683-92.
55 Harenberg J, Heene D L. Pharmacology and special clinical applications of lowmolecular-weight heparins. Am J Hematol 1988; 29: 233-40.
56 Harenberg J, Leber G, Augustin J, Raedsch R, Schwarz F, Stiehl A, Zimmermann R. Ambulante Langzeitprophylaxe der Thromboembolie mit niedermolekularem Heparin. Klin Wochenschr 1987; 65: 331-7.
57 Harenberg J, Schwarz F, Dietz R, Leber G, Zimmermann R, Kübler W. Antikoagulation mit niedermolekularem Heparin bei Patienten mit prothetischem Herzklappenersatz. Z Kardiol 1987; 76: 284-8.
58 Harenberg J, Stehle G, Dempfle C E, von Hodenberg E, Heene D L. Beeinflussung der Blutgerinnung und der Lipasen durch das niedermolekulare Heparin CY 216. Ärztl Lab 1989; 35: 73-9.
59 Harenberg J, Weuster B, Pfitzer M, Stehle G, Schlief G. Prospective, randomised controlled study on the prophylaxis of embolism in patients with atrial fibrillation. Thromb Haemost 1989; 62: 1870 (abstr).
60 Harenberg J, Würzner B, Zimmermann R, Schettler G. Bioavailability and antagonization of the low-molecular-weight heparin CY 216 in man. Thromb Res 1986; 44: 549-54.
61 Harenberg J, Würzner B, Zimmermann R, Schettler G. Pharmakologisches Profil niedermolekularer Heparine. Med Klin 1986; 81 Suppl III: 4-8.
62 Harenberg J, Leber G, Dempfle C E, Heene D L, Zimmermann R, Kübler W. Long term anticoagulation with low molecular weight heparin in outpatients with side effects of oral anticoagulants. Nouv Rev Franc d’Hématol. 1989 (in press).
63 Harenberg J, Leber G, Zimmermann R, Schmidt W. Thromboembolieprophylaxe mit niedermolekularem Heparin in der Schwangerschaft. Geburtsh u Frauenheilk 1987; 47: 15-18.
64 Harris A W, Levine S A. Cerebral embolism in mitral stenosis. Ann Int Med 1941; 15: 637-43.
65 Hart R G, Easton J D. Hemorrhagic infarcts. Stroke 1986; 17: 586-9.
66 Hart R G, Coull B M, Hart D. Early recurrent embolism associated with non valvular atrial fibrillation: a retrospective study. Stroke 1983; 14: 688-93.
67 Hinton R C, Kistler J P, Fallon J T, Friedlich A L, Fisher C M. Influence of etiology of atrial fibrillation on incidence of systemic embolism. Am J Cardiol 1977; 40: 509-13.
68 Hirsh J, Barrowcliffe T W. Standardization and clinical use of LMW heparin. Thromb Haemost 1988; 59: 333.
69 Holmer E, Kurachi K, Söderström G. The molecular-weight dependence of the rateenhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIIa and kallikrein by antithrombin. Biochem J 1981; 193: 395-400.
70 Holmer E, Mattson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin in rabbits. Thromb Res 1982; 25: 475-85.
71 Holmer E, Söderström G, Andersson L O. Studies on the mechanism of the rateenhancing effect of heparin on the thrombin-antithrombin III reaction. Eur J Biochem 1979; 93: 1.
72 Jörgensen L, Torvik A. Ischaemic cerebrovascular diseases in an autopsy series. Part 2. Prevalence, location, pathogenesis, and clinical course of cerebral infarcts. J Neurol Sci 1969; 09: 285-320.
73 Kakkar V V, Murray W J G. Efficacy and safety of low-molecular-weight heparin (CY 216) in preventing postoperative venous thromboembolism: a cooperative study. Br J Surg 1985; 72: 786-91.
74 Kakkar V V. Wirksamkeit und Verträglichkeit der niedermolekularen Heparinfraktion CY 216 bei der Prophylaxe postoperativer venöser thromboembolischer Prozesse. Med Klin. 1986 81. Suppl. III.
75 Kakkar V V, Djazaeri B, Fok J, Fletcher M, Scully M F, Westwick J. Low-molecular-weight heparin and prevention of postoperative deep-vein thrombosis. Br Med J 1982; 284: 375-9.
76 Kannel W B, Abbott R D, Savage D D, McNamara M P. Epidemiologic features of chronic atrial fibrillation. The Framingham Study. N Engl J Med 1982; 306: 1018-22.
77 Kelley R E, Berger I R, Alter M, Kovacs A G. Cerebral ischemia and atrial fibrillation: a prospective study. Neurology 1984; 34: 1285-91.
78 Kelton J G, Hirsh J. Bleeding associated with antithrombotic therapy. Semin Hematol 1980; 17: 259-91.
79 Koller R L. Recurrent embolic cerebral infarction and anticoagulation. Neurology 1982; 32: 283-5.
80 Kopecky S L, Gersh B J, McGoon M D, Whisnant J P, Holmes D R, Ilstrup D N, Frye R L. The natural history of lone atrial fibrillation. A population-based study over three decades. N Engl J Med 1985; 317: 669-74.
81 Kulbertus H E, de Laval-Rutten, Bartsch P, Petit J M. Atrial fibrillation in elderly, ambulatory patients. In: Atrial Fibrillation. Kulbertus H E, Olsson S B, Schlepper M. (eds). 2nd ed. Mölndal (Schweden):. Hässle AB; 1984
82 Lane D A, Denton J, Flynn A M, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-32.
83 Lane D A, MacGregor I R, Van Ross M, Cella G, Kakkar V V. Molecular weight dependence of the anticoagulant properties of heparin: intravenous and subcutaneous administration of fractionated heparins to man. Thromb Res 1979; 16: 651-62.
84 Lane D A, Pejler G, Flynn A M, Thompson E A, Lindahl U. Neutralization of heparin-related saccharides by histidinerich glycoprotein and platelet factor 4. J Biol Chem 1986; 261: 3980-6.
85 Lane D A. Heparin binding and neutralizing proteins. In: Heparin. Chemical and Biological Properties. Clinical Applications. Lane D A, Lindahl U. (eds). London, Melbourne Auckland: Edwald Arnold; 1989: 383-92.
86 Levin M N, Raskob G, Hirsh J. Risk of haemorrhage associated with long-term anticoagulant therapy. Drugs 1985; 30: 444-60.
87 Lieberman A, Hass W K, Pinto R, Isom W O, Kupersmith M, Bear G, Chase R. Intracranial hemorrhage and infarction in anticoagulated patients with prosthetic heart valves. Stroke 1978; 09: 18-24.
88 Lodder J. CT-detected hemorrhagic infarction; relation with the size of the infarct and the presence of midline shift. Acta Neurol Scand 1984; 70: 329-335.
89 Loeliger E A, Hensen A, Kroes F, van Dijk L M, Fekes M, de Jonge H, Hemker H C. A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 1967; 182: 549-66.
90 Monreal M, Foz M, Audi L. Warfarin to prevent thromboembolism in chronic atrial fibrillation. (Letter to the Edito)r. Lancet 1989; I: 670.
91 Nielsen J D, Klosteroskov-Jensen P, Jorgensen M. Changes in fibrinolytic activity and platelet aggregation after stroke and TIA. Thromb Haemost 1989; 62: 327 (abstr).
92 Oosta G M, Gardner W T, Beeler D L, Rosenberg R D. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci 1981; 78: 829-33.
93 Ott B R, Zamani A, Kleefield J, Funkenstein H H. The clinical spectrum of hemorrhagic infarction. Stroke 1986; 17: 590-3.
94 Peter R H, Gracey J G, Beach T B. A clinical profile of idiopathic atrial fibrillation. Ann Int Med 1968; 68: 1288-90.
95 Petersen P, Boysen G, Godtfredsen J, Andersen E D, Andersen B. Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989; I: 175-8.
96 Petersen P, Boysen G, Godtfredsen J, Anderson E D, Andersen B. Warfarin to prevent thromboembolism in chronic atrial fibrillation. (Letter to the Editor). Lancet 1989; I: 670.
97 Petitti D B, Strom B L, Melmon K L. Duration of warfarin therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med 1986; 81: 255-9.
98 Roos J, van Joost H. The cause of bleeding during anticoagulant treatment. Acta Med Scand 1965; 178: 129-31.
99 Rosenberg R D, Damus P S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-505.
100 Rosenberg R D, Jordan R E, Favreau L K, Lam L H. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Comm 1979; 86: 1319-24.
101 Rosenberg R D. Actions and interactions of antithrombin and heparin. N Engl J Med 1975; 292: 146-51.
102 Roy D, Marchand E, Gagne P, Chabot M, Cartier R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986; 112: 1039-43.
103 Sage P, van Uitert R L. Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease. Stroke 1983; 14: 537-40.
104 Santamaria J, Graus F, Peres J. Cerebral embolism and anticoagulation (Letter to the Editor). Neurology 1983; 33: 1104.
105 Scardi S, Ceschia G, Pandullo C, Benettoni A, Pivotti F. La storia naturale dei pazienti con fibrillazione atriale isolata. G Ital Cardiol 1987; 17: 492-7.
106 Sherman D G, Hart R G, Easton J D. The secondary prevention of stroke in patients with atrial fibrillation. Arch Neurol 1986; 43: 68-70.
107 Sherman D G, Goldman L, Whiting R B. Risk of thromboembolism in patients with atrial fibrillation. Arch Neurol 1984; 41: 708-10.
108 Shields Jr. R W, Laureno R, Lachman T, Victor M. Anticoagulant-related hemorrhage in acute cerebral embolism. Stroke 1984; 15: 426-37.
109 Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1982; I: 64-8.
110 Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. Br Med J 1964; 01: 1209-12.
111 Ten Cate H, Henny C P, Büller H R, Ten Cate J W, Magnani H N. Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease. Ann Neurol 1984; 15: 268-70.
112 The European Fraxiparin Study (EFS) Group. Comparison of a low molecular weight heparin and a unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988; 75: 1058-63.
113 Thomas D P, Merton R E. A low-molecular-weight heparin compared with unfractionated heparin. Thromb Res 1982; 28: 343-51.
114 Treseder A S, Sastry B S D, Thomas T P L, Yates M A, Pathy M S J. Atrial fibrillation and stroke in elderly hospitalized patients. Age Ageing 1986; 15: 89-92.
115 Turpie A G G, Hirsh J, Jay R M, Andrew M, Hull R D, Levine M N, Carter C J, Powers P J, Magnani H N, Gent M. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987; I: 523-6.
116 Uno M, Tsuji H, Sawada S, Toyoda T, Nakagawa M. Fibrinopeptide A (FPA) levels in atrial fibrillation and the effects of heparin administration. Jpn Cire J 1988; 52: 9-12.
117 Vairel E G, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh N A, Gaffney P J. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-24.
118 Verheugt F W A, Galema T W. Warfarin to prevent thromboembolism in chronic atrial fibrillation. (Letter to the Editor). Lancet 1989; I: 670.
119 Vinazzer H, Sternberger A, Haas S, Bliimel G. Influence of heparin, of different heparin fractions and of low molecular weight heparin-like substance on the mechanism of fibrinolysis. Thromb Res 1982; 27: 431-52.
120 Walker M D. Atrial fibrillation and antithrombotic prophylaxis: a prospective meta-analysis. Lancet 1989; I: 326.
121 Weiss S, Davis D. Rheumatic heart disease. III. Embolic manifestations. Am Heart J 1933; 09: 45-52.
122 Wiener I, Hafner R, Nicolai M, Lyons H. Clinical and echocardiographic correlates of systemic embolization. Am J Cardiol 1987; 59: 177.
123 Wintzen A R, De Jonge H, Loeliger E A, Bots G T AM. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 1984; 16: 553-8.
124 Wintzen A R, Tijssen J G P. Subdural hematoma and oral anticoagulant therapie. Arch Neurol 1982; 39: 69-72.
125 Wolf P A, Abbott R D, Kannel W B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Int Med 1987; 147: 1561-4.
126 Wolf P A, Dawber T R, Thomas Jr. H E, Kannel W B. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham Study. Neurology 1978; 28: 973-7.
127 Wolf P A, Kannel W B, McGee D L, Meeks S L, Bharucha N E, McNamara P M. Duration of atrial fibrillation and imminence of stroke: The Framingham Study. Stroke 1983; 14: 664-7.